Five Star Stock Watch

Trading the stock market has been somewhat of a challenge over the last month or so. Is it going back up? Has it finally started the long awaited correction? Should traders be on the long side or the short side? Trying to get on the right side of those questions has been tough to do. And of...

While the overall stock market has been pulling back over the last three days, the biotech space has been taken out to the woodshed. Considering that biotech stocks were once among the hottest in the entire market, it's not too surprising that once the levy broke, investors started running...

Biotech stocks have been breaking to new highs all over the market. Here are just a few: Esperion Therapeutics broke to a new high last week and skyrocketed Tuesday. Ampio Pharmaceuticals bolted higher last week and touched a new high Wednesday. Jazz Pharmaceuticals just hit a new...

When the market gets a little sketchy, investors might tend to prefer the "blue chip" companies vs. the smaller companies due to the perceived safety in the bigger names. To isolate those bigger names, the most common method is by searching for companies with the largest market...

Approximately two weeks ago the S&P 500 finally broke through its 2065 resistance. At the same time, the Nasdaq Composite pushed above its 4800 resistance. Expectations at that time would have been for higher prices, and that’s exactly what the market has given investors since those...

<em>Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.</em> For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the...

This article is written by Christian Tharp, the author of 5 Star Trading. The S&P 500 hit its last all-time high back at the end of 2014, and has chopped lower since. The Nasdaq has fared a bit better over that stretch, but the index still has yet to hit a new bull market high since...

Biotech is big, and the industry has been big for quite some time. As a matter of fact, biotechnology has been the second-best performing industry over the last two years. Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the...

Rumor has it that if the S&P 500 finishes its first five trading days of the year with a gain, then the year in question will -- 80 percent of the time -- end with a gain as well. Last Thursday’s rally gave the S&P that five-day gain. However, since that day, the market has seen a...

Stocks have been getting hit pretty hard over the last week. The new year has started off somewhat like 2014 did -- down. Some individual industries are holding up a little better than others, such as gold miners, REITs and airlines. Biotech stocks have held on relatively well, too. Biotech...

After last week’s hammering of biotech stocks, many have not been able to recover to hit new highs with the overall market. Previous high flyers such as Agios Pharmaceuticals Inc (NASDAQ: AGIO) and Receptos Inc (NASDAQ: RCPT) have bounced, but still lag the Nasdaq. Others, such as...

This week brings to close yet another year of gains for the stock market, the sixth straight year in this bull run. The benchmark S&P 500 started off 2014 at 1848 and as of Friday the index sat at 2088. Some of the top industries of the year include airlines, semiconductors,...

Many biotech stocks have been breaking out over the past two months. Newlink Genetics Corp and Incyte Corporation both skyrocketed in October. After that, stocks of Ariad Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. both had nice, quick pops last month. Then...